首页|血清GDF-8、VEGF、FGF21水平与肝硬化患者肌肉减少症发生的关系

血清GDF-8、VEGF、FGF21水平与肝硬化患者肌肉减少症发生的关系

The relationship between serum GDF-8,VEGF,FGF21 expression levels and the occurrence of sarcopenia in patients with cirrhosis

扫码查看
目的 探究血清生长分化因子-8(GDF-8)、血管内皮生长因子(VEGF)、成纤维细胞生长因子21(FGF21)水平与肝硬化患者发生肌肉减少症(肌少症)的关系.方法 选取2022年1月-2024年3月陕西省人民医院消化内科诊治的肝硬化并发肌少症患者63例为观察组,根据肌少症分期将肝硬化并发肌少症患者分为肌少症前期亚组22例、肌少症期亚组25例、重度肌少症期亚组16例.另选取同期医院肝硬化患者60例为对照组.采用酶联免疫吸附试验(ELISA)测定血清GDF-8、VEGF、FGF21水平;Spearman相关性分析血清GDF-8、VEGF、FGF21水平与肝硬化并发肌少症患者肌少症分期的关系;多因素Logistic回归分析肝硬化患者并发肌少症的影响因素;受试者工作特征(ROC)曲线评价血清GDF-8、VEGF、FGF21水平对肝硬化患者并发肌少症的预测价值.结果 观察组血清GDF-8、FGF21水平高于对照组,血清VEGF水平低于对照组(t=7.719、10.011、11.837,P均<0.001);随着肌少症疾病分期进展,肝硬化并发肌少症患者血清GDF-8、FGF21水平逐渐升高,血清VEGF水平逐渐降低(F=16.605、15.527、19.995,P均<0.001);Spearman相关性分析结果显示,肝硬化并发肌少症患者血清GDF-8、FGF21水平与肌少症分期呈正相关(r=0.760、0.525,P均<0.01),血清VEGF水平与肌少症分期呈负相关(r=-0.546,P<0.01);多因素Logistic回归分析结果示,糖尿病病史、GDF-8高、FGF21高是肝硬化患者并发肌少症的独立危险因素[OR(95%CI)=2.496(1.315~4.738)、2.115(1.377~3.249、2.894(1.598~5.241)],BMI 高、RASM 高、VEGF 高是独立保护因素[OR(95%CI)=0.618(0.461~0.828)、0.573(0.370~0.887)、0.469(0.307~0.718)];血清 GDF-8、VEGF、FGF21 水平及三者联合预测肝硬化患者并发肌少症的曲线下面积(AUC)分别为0.836、0.912、0.921、0.980,三者联合的AUC大于血清 GDF-8、VEGF、FGF21 水平单独预测的 AUC(Z/P=3.878/<0.001、2.954/0.003、2.678/0.007).结论 血清GDF-8、VEGF、FGF21水平与肝硬化患者发生肌少症密切相关,检测三者血清水平可能对肝硬化患者并发肌少症的预测有一定的临床价值.
Objective To investigate the relationship between the expression levels of serum growth differentiation factor-8(GDF-8),vascular endothelial growth factor(VEGF),and fibroblast growth factor 21(FGF21)and the occurrence of sarcopenia in patients with liver cirrhosis.Methods From January 2022 to March 2024,63 patients with liver cirrhosis com-plicated with sarcopenia treated in our hospital were included as the sarcopenia group,and 60 patients with liver cirrhosis were included as the control group.The serum levels of GDF-8,VEGF,and FGF21 were compared.Spearman correlation was applied to analyze the relationship between serum GDF-8,VEGF,FGF21 levels and sarcopenia staging.Logistic regression was applied to analyze the factors affecting the occurrence of sarcopenia in patients with cirrhosis.Receiver operating char-acteristic(ROC)curves were applied to analyze the predictive value of serum GDF-8,VEGF,and FGF21 levels for the devel-opment of sarcopenia in patients with cirrhosis.Results The levels of GDF-8 and FGF21 in the serum of patients with liver cirrhosis complicated with sarcopenia were greatly higher,while the level of VEGF was greatly lower(t=7.719,10.011,11.837,all P<0.001).The levels of GDF-8 and FGF21 in serum gradually increased with the progression of sarcopenia,while the level of VEGF gradually decreased with the progression of sarcopenia(F=16.605,15.527,19.995,all P<0.001).The levels of serum GDF-8 and FGF21 in patients were positively correlated with the stage of sarcopenia(r=0.760,0 525,P<0.05),while the level ofVEGF was negatively correlated with the stage of sarcopenia(r=-0.546,P<0.05).There were great differences between the control group and the sarcopenia group in BMI,the proportion of diabetes history,grip strength,walking speed,RASM,and high-density lipoprotein levels(P<0.05).The history of diabetes(OR=2.496,95%CI 1 315-4.738),the increase of serum GDF-8(OR=2.115,95%CI 1377-3249)and FGF21(OR=2.894,95%CI 1.598-5 241)levels were risk fac-tors for sarcopenia in patients with cirrhosis(P<0.05),and high BMI(OR=0.618,95%CI 0.461-0.828),RASM(OR=0.573,95%CI0.370-0.887)and VEGF(OR=0.469,95%CI0.307-0.718)levels were protective factors(P<0.05).The area under the curve(AUC)of serum GDF-8,VEGF,and FGF21 levels in predicting sarcopenia in patients with cirrhosis was 0.836,0.912,and 0.921,respectively.The AUC of the combined detection of the three was 0.980,which was better than that of the individual detection(Z/P=3.878/<0.001、2.954/0.003、2.678/0.007).Conclusion The levels of serum GDF-8,VEGF,and FGF21 are closely related to the occurrence of sarcopenia in patients with cirrhosis.Detecting the levels of the three in serum may have certain clinical value for predicting the occurrence of sarcopenia in patients with cirrhosis.

CirrhosisSarcopeniaGrowth differentiation factor-8Vascular endothelial growth factorFibroblast growth factor 21

金燕、王雪、阎春英、段天娇、白改艳、张蓉

展开 >

710068 西安,陕西省人民医院消化内科

肝硬化 肌肉减少症 生长分化因子-8 血管内皮生长因子 成纤维细胞生长因子21

2024

疑难病杂志
中国医师协会

疑难病杂志

CSTPCD
影响因子:1.171
ISSN:1671-6450
年,卷(期):2024.23(12)